Sotatercept demonstrated significant improvement in exercise capacity and key secondary outcome measures compared to placebo when added to background therapy
WINREVAIR met primary endpoint of time to first morbidity or mortality event for the treatment of patients with pulmonary arterial hypertension (PAH) functional class III or IV at high risk of mortality
Winrevair is the first activin signaling inhibitor therapy for PAH approved in Europe
Sales reflect continued strong growth in oncology and vaccines
WINREVAIR is a breakthrough biologic for this rare, progressive disease
The acquisition complements and strengthens Merck’s cardiovascular pipeline
Subscribe To Our Newsletter & Stay Updated
